长新冠中新发糖尿病的风险与负担:一项队列研究
该队列研究基于美国退伍军人事务部国家数据库,纳入181280例SARS-CoV-2感染存活者、4118441例同期对照和4286911例历史对照,随访中位352天。结果显示,感染后急性期新发糖尿病风险升高(HR 1.40,95%CI 1.36-1.44),12个月每1000人超额负担13.46例,且风险随急性期严重程度呈梯度增加。
要点
- COVID-19存活者急性期后新发糖尿病风险升高(HR 1.40,95%CI 1.36-1.44)。
- 12个月每1000人新发糖尿病超额负担为13.46例(95%CI 12.11-14.84)。
- 风险与负担随急性期严重程度(非住院、住院、ICU)呈梯度增加。
核心结论
- COVID-19急性期后,与同期未感染SARS-CoV-2的对照和疫情前历史对照相比,新发糖尿病及抗高血糖药物使用的风险和12个月负担均升高。
研究设计与样本
- 队列研究,使用美国退伍军人事务部国家数据库,纳入COVID-19检测阳性且存活30天者181280例、同期对照4118441例、历史对照4286911例。
主要发现
- 与同期对照相比,COVID-19组新发糖尿病风险HR 1.40(95%CI 1.36-1.44),12个月每1000人超额负担13.46(95%CI 12.11-14.84)。
- 与同期对照相比,COVID-19组新发抗高血糖药物使用风险HR 1.85(95%CI 1.78-1.92),12个月每1000人超额负担12.35(95%CI 11.36-13.38)。
- 与同期对照相比,COVID-19组新发糖尿病或抗高血糖药物使用复合终点风险HR 1.46(95%CI 1.43-1.50),12个月每1000人超额负担18.03(95%CI 16.59-19.51)。
- 急性期后结局的风险和负担随COVID-19急性期严重程度(非住院、住院、ICU)呈梯度增加。
- 使用历史对照的分析结果一致。
临床怎么用
- COVID-19急性期后护理应包含糖尿病的识别与管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is growing evidence suggesting that beyond the acute phase of SARS-CoV-2 infection, people with COVID-19 could experience a wide range of post-acute sequelae, including diabetes. However, the risks and burdens of diabetes in the post-acute phase of the disease have not yet been comprehensively characterised. To address this knowledge gap, we aimed to examine the post-acute risk and burden of incident diabetes in people who survived the first 30 days of SARS-CoV-2 infection. METHODS: In this cohort study, we used the national databases of the US Department of Veterans Affairs to build a cohort of 181 280 participants who had a positive COVID-19 test between March 1, 2020, and Sept 30, 2021, and survived the first 30 days of COVID-19; a contemporary control (n=4 118 441) that enrolled participants between March 1, 2020, and Sept 30, 2021; and a historical control (n=4 286 911) that enrolled participants between March 1, 2018, and Sept 30, 2019. Both control groups had no evidence of SARS-CoV-2 infection. Participants in all three comparison groups were free of diabetes before cohort entry and were followed up for a median of 352 days (IQR 245-406). We used inverse probability weighted survival analyses, including predefined and algorithmically selected high dimensional variables, to estimate post-acute COVID-19 risks of incident diabetes, antihyperglycaemic use, and a composite of the two outcomes. We reported two measures of risk: hazard ratio (HR) and burden per 1000 people at 12 months. FINDINGS: In the post-acute phase of the disease, compared with the contemporary control group, people with COVID-19 exhibited an increased risk (HR 1·40, 95% CI 1·36-1·44) and excess burden (13·46, 95% CI 12·11-14·84, per 1000 people at 12 months) of incident diabetes; and an increased risk (1·85, 1·78-1·92) and excess burden (12·35, 11·36-13·38) of incident antihyperglycaemic use. Additionally, analyses to estimate the risk of a composite endpoint of incident diabetes or antihyperglycaemic use yielded a HR of 1·46 (95% CI 1·43-1·50) and an excess burden of 18·03 (95% CI 16·59-19·51) per 1000 people at 12 months. Risks and burdens of post-acute outcomes increased in a graded fashion according to the severity of the acute phase of COVID-19 (whether patients were non-hospitalised, hospitalised, or admitted to intensive care). All the results were consistent in analyses using the historical control as the reference category. INTERPRETATION: In the post-acute phase, we report increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during the same period and had not contracted SARS-CoV-2, and a historical control group from a pre-pandemic era. Post-acute COVID-19 care should involve identification and management of diabetes. FUNDING: US Department of Veterans Affairs and the American Society of Nephrology.
引用
- Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022. PMID: 35325624. doi:10.1016/S2213-8587(22)00044-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。